Thomas Sciascia - Aug 14, 2024 Form 4 Insider Report for Trevi Therapeutics, Inc. (TRVI)

Role
Chief Scientific Officer
Signature
/s/ Christopher Galletta, attorney-in-fact
Stock symbol
TRVI
Transactions as of
Aug 14, 2024
Transactions value $
-$42,176
Form type
4
Date filed
8/16/2024, 04:47 PM
Previous filing
May 31, 2024
Next filing
Aug 21, 2024

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction TRVI Common Stock Options Exercise $143 +100 +0.05% $1.43 220K Aug 14, 2024 Direct F1
transaction TRVI Common Stock Sale -$275 -100 -0.05% $2.75 220K Aug 14, 2024 Direct
transaction TRVI Common Stock Options Exercise $18.2K +12.7K +5.78% $1.43 233K Aug 15, 2024 Direct
transaction TRVI Common Stock Sale -$35.5K -12.7K -5.47% $2.79 220K Aug 15, 2024 Direct F2
transaction TRVI Common Stock Options Exercise $26.7K +18.7K +8.47% $1.43 239K Aug 16, 2024 Direct
transaction TRVI Common Stock Sale -$51.4K -18.7K -7.81% $2.76 220K Aug 16, 2024 Direct F3

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction TRVI Stock Option (right to buy) Options Exercise $0 -100 -0.21% $0.00 47.9K Aug 14, 2024 Common Stock 100 $1.43 Direct F4
transaction TRVI Stock Option (right to buy) Options Exercise $0 -12.7K -26.61% $0.00 35.2K Aug 15, 2024 Common Stock 12.7K $1.43 Direct F4
transaction TRVI Stock Option (right to buy) Options Exercise $0 -18.7K -53.08% $0.00 16.5K Aug 16, 2024 Common Stock 18.7K $1.43 Direct F4
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Includes 5,882 shares purchased through the Issuer's employee stock purchase plan.
F2 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $2.75 to $2.8020 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above.
F3 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $2.75 to $2.77 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above.
F4 This option was granted on November 25, 2014. The 48,001 shares of common stock underlying the option vested as to 25% of the shares on November 25, 2015 and vested as to the remaining 75% of the shares in equal monthly installments thereafter through November 25, 2018.